SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2764)10/22/2019 8:12:36 AM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 3557
 
...2Q 2018 Ex-US Lucentis sale was also weak relative to 2Q/4Q...
Did you mean to say 3Q 2018?



To: Miljenko Zuanic who wrote (2764)10/30/2019 3:03:33 AM
From: Miljenko Zuanic  Respond to of 3557
 
Eylea, ex-US sale, reported by Bayer, were e640M for 3Q-19, relative to e541M for 3Q-18, 18.3% growth. At e = 1.11 US $, it is $710.4M. However, as reported of 15.9% growth v 3Q-18 (at cer, was $654.6M), Eylea 3Q-19 sale should be ~$758.7M...which is by $43.4M higher than 2Q-19 ($715.3M).
So, my prediction of ex-US bit-growth for 3Q (relative to Lucentis bit-decline) was correct.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News